Published in Drug Week, February 17th, 2006
"Most cancer pharmacogenetic studies use germline DNA, as tumor tissue is often inaccessible in the advanced disease setting. However, this relies on the assumption that germline DNA is representative of the tumor genotype," investigators in the United States reported.
"To date, there has been little attention paid to defining the relationship between tumor and germline genomes. This study compared 28 polymorphisms in 13 genes of high importance to cancer pharmacogenetics from 10 different chromosome regions, in DNA from normal mucosa and colon tumors in 44 paired...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.